UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB





( ) QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934 FOR THE QUARTERLY PERIOD ENDED MAY 31, 2003


( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934 For the transition period from                 to
                                          ----------------    ------------------

Commission File Number: 000-31567


                           Rapid Bio Tests Corporation
                           ---------------------------
        (Exact name of small business issuer as specified in its charter)

Nevada                                                               35-0511303
------                                                               ----------
(State or other jurisdiction of            (I.R.S. Employer Identification No.)
incorporation or organization)

                        5409 Ivy Street, Springfield, Oregon 97478
-------------------------------------------------------------------------------
                         (Address of principal executive offices)


                                  (541)686.5989
                                  -------------
                           (Issuer's Telephone Number)



                      APPLICABLE ONLY TO CORPORATE ISSUERS


State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practical date. As of July 9, 2003 there were
30,114,214 shares of the issuer's $.001 par value common stock issued and
outstanding.



                                       1
<PAGE>



ITEM 1.  FINANCIAL STATEMENTS
-----------------------------



                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)

                              FINANCIAL STATEMENTS

                       May 31, 2003 and February 28, 2003





                                       2
<PAGE>



                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                                 Balance Sheets




<TABLE>
<CAPTION>
                                     ASSETS
                                     ------
                                                                                 May 31,           February 28,
                                                                                  2003                 2003
                                                                           -----------------     -----------------
                                                                               (Unaudited)
<S>                                                                                <C>                  <C>
CURRENT ASSETS

   Cash                                                                    $               -     $               -
                                                                           -----------------     -----------------

     Total Current Assets                                                                  -                     -
                                                                           -----------------     -----------------

     TOTAL ASSETS                                                          $               -     $               -
                                                                           =================     =================


                 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
                 ----------------------------------------------

CURRENT LIABILITIES

   Accounts payable                                                        $          14,335    $           12,308
   Accounts payable - related parties                                                 42,236                40,941
   Accrued expenses                                                                    5,000                 5,000
                                                                           -----------------    ------------------

     Total Current Liabilities                                                        61,571                58,249
                                                                           -----------------    ------------------

     Total Liabilities                                                                61,571                58,249
                                                                           -----------------    ------------------

STOCKHOLDERS' EQUITY (DEFICIT)

   Common stock, par value $0.001; authorized
     120,000,000 shares; 114,214 shares issued
     and outstanding                                                                     114                   114
   Additional paid-in capital                                                        795,537               795,537
   Deficit accumulated prior to the development stage                               (989,057)             (989,057)
   Retained earnings during the development stage                                    131,835               135,157
                                                                           -----------------     -----------------

     Total Stockholders' Equity (Deficit)                                            (61,571)              (58,249)
                                                                           -----------------    ------------------

     TOTAL LIABILITIES AND STOCKHOLDERS'
      EQUITY (DEFICIT)                                                     $               -    $                -
                                                                           =================    ==================
</TABLE>



The accompanying notes are an integral part of these financial statements.

                                       3
<PAGE>



                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                            Statements of Operations
                                   (Unaudited)


<TABLE>
<CAPTION>
                                                                                        From
                                                                                      Inception
                                                                                       Of the
                                                                                     Development
                                                             For the                  Stage on
                                                       Three Months Ended             March 1,
                                                             May 31,                2001 through
                                               ---------------------------------       May 31,
                                                    2003             2002               2003
                                               ---------------   ---------------  ----------------
<S>                                                 <C>               <C>               <C>
REVENUES                                       $             -   $             -  $              -
                                               ---------------   ---------------  ----------------

EXPENSES

   General and administrative                            2,824             3,255            44,662
                                               ---------------   ---------------  ----------------

     Total Expenses                                      2,824             3,255            44,662
                                               ---------------   ---------------  ----------------

LOSS FROM OPERATIONS                                    (2,824)           (3,255)          (44,662)
                                               ---------------   ---------------  ----------------

OTHER INCOME (EXPENSE)

   Gain on extinguishments of debt                           -                 -           189,233
   Interest expense                                       (498)             (450)          (12,736)
                                               ---------------   ---------------  ----------------

     Total Other Income (Expense)                         (498)             (450)          176,497
                                               ---------------   ---------------  ----------------

INCOME (LOSS) BEFORE INCOME TAXES                       (3,322)           (3,705)          131,835

   Income taxes                                              -                 -                 -
                                               ---------------   ---------------  ----------------

NET INCOME (LOSS)                              $        (3,322)  $        (3,705) $        131,835
                                               ===============   ===============  ================

BASIC LOSS PER SHARE                           $         (0.03)  $         (0.03)
                                               ===============   ===============

WEIGHTED AVERAGE NUMBER OF
 SHARES OUTSTANDING                                    114,214           114,214
                                               ===============   ===============
</TABLE>




The accompanying notes are an integral part of these financial statements.

                                       4
<PAGE>



                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                  Statements of Stockholders' Equity (Deficit)

<TABLE>
<CAPTION>
                                                                                                        Deficit        Retained
                                                                                                      Accumulated      Earnings
                                                           Common                   Additional       Prior to the     During the
                                              --------------------------------        Paid-in         Development   Development
                                                  Shares            Amount            Capital           Stage            Stage
                                              ---------------  ---------------   ----------------  ---------------  ---------------
<S>                                                 <C>              <C>                <C>               <C>             <C>
Balance, February 28, 2001                             39,614  $            39   $        563,971  $      (989,057) $             -

Common stock issued in satisfaction
 of debt at $0.123 per share,
 December 17, 2001                                      7,000                7            214,734                -                -

Common stock issued in satisfaction
 of debt at $0.001 per share,
 January 28, 2002                                       4,000                4                996                -                -

Common stock issued for services
 at $0.001 per share,
 February 1, 2002                                      63,600               64             15,836                -                -

Net income for the year ended
 February 28, 2002                                          -                -                  -                -           90,714
                                             ----------------  ---------------   ----------------  ---------------  ---------------

Balance, February 28, 2002                            114,214              114            795,537         (989,057)          90,714

Net income for the year ended
 February 28, 2003                                          -                -                  -                -           44,443
                                             ----------------  ---------------   ----------------  ---------------  ---------------

Balance, February 28, 2003                           114, 214              114            795,537         (989,057)         135,157

Net loss for the three months ended
 May 31, 2003 (unaudited)                                   -                -                  -                -           (3,322)
                                             ----------------  ---------------   ----------------   --------------  ---------------

Balance, May 31, 2003 (unaudited)                     114,214  $           114   $        795,537   $     (989,057) $       131,835
                                             ================  ===============   ================   ==============  ===============
</TABLE>





The accompanying notes are an integral part of these financial statements.

                                       5
<PAGE>



                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                            Statements of Cash Flows
                                   (Unaudited)


<TABLE>
<CAPTION>

                                                                                                         From
                                                                                                       Inception
                                                                                                        Of the
                                                                                                      Development
                                                                                                       Stage on
                                                                   For the Three Months Ended          March 1,
                                                                             May 31,                 2001 through
                                                               ---------------------------------        May 31,
                                                                     2003              2002              2003
                                                               ---------------   ---------------  ----------------
<S>                                                                  <C>               <C>               <C>
CASH FLOWS FROM OPERATING ACTIVITIES

   Net income (loss)                                           $        (3,322)  $        (3,705) $        131,835
   Adjustments to reconcile loss from operations
    to net cash used by operating activities:
     Gain on extinguishments of debt                                         -                 -          (189,233)
     Common stock issued for services                                        -                 -            15,900
   Changes in assets and liabilities:
     Increase in accrued interest                                            -               450            10,347
     Increase in accounts payable and
      accounts payable - related parties                                 3,322             3,255            26,151
     Increase in accrued expenses                                            -                 -             5,000
                                                               ---------------   ---------------  ----------------

       Net Cash (Used by) Operating Activities                               -                 -                 -
                                                               ---------------   ---------------  ----------------

CASH FLOWS FROM INVESTING ACTIVITIES                                         -                 -                 -
                                                               ---------------   ---------------  ----------------

CASH FLOWS FROM FINANCING ACTIVITIES                                         -                 -                 -
                                                               ---------------   ---------------  ----------------

NET INCREASE (DECREASE) IN CASH                                              -                 -                 -

CASH AT BEGINNING OF PERIOD                                                  -                 -                 -
                                                               ---------------   ---------------  ----------------

CASH AT END OF PERIOD                                          $             -   $             -  $              -
                                                               ===============   ===============  ================

SUPPLEMENTAL CASH FLOW INFORMATION:

   Cash paid for:

     Interest                                                  $             -   $             -  $              -
     Income taxes                                              $             -   $             -  $              -

NON-CASH FINANCING AND INVESTING ACTIVITIES:

     Common stock issued in lieu of debt                       $             -   $             -  $        215,741
     Common stock issued for services                          $             -   $             -  $         15,900
</TABLE>




The accompanying notes are an integral part of these financial statements.

                                       6
<PAGE>



                           RAPID BIO TESTS CORPORATION
                           (Formerly Vitatonics Corp.)
                          (A Development Stage Company)
                        Notes to the Financial Statements
                       May 31, 2003 and February 28, 2003


NOTE 1 -     BASIS OF FINANCIAL STATEMENT PRESENTATION

             The accompanying unaudited condensed financial statements have been
             prepared by the Company pursuant to the rules and regulations of
             the Securities and Exchange Commission. Certain information and
             footnote disclosures normally included in financial statements
             prepared in accordance with accounting principles generally
             accepted in the United States of America have been condensed or
             omitted in accordance with such rules and regulations. The
             information furnished in the interim condensed financial statements
             include normal recurring adjustments and reflects all adjustments,
             which, in the opinion of management, are necessary for a fair
             presentation of such financial statements. Although management
             believes the disclosures and information presented are adequate to
             make the information not misleading, it is suggested that these
             interim condensed financial statements be read in conjunction with
             the Company's most recent audited financial statements and notes
             thereto included in its February 28, 2003 Annual Report on Form
             10-KSB. Operating results for the three months ended May 31, 2003
             are not necessarily indicative of the results that may be expected
             for the year ending February 28, 2004.

NOTE 2 -      GOING CONCERN

              The Company's financial statements are prepared using accounting
              principles generally accepted in the United States of America
              applicable to a going concern which contemplates the realization
              of assets and liquidation of liabilities in the normal course of
              business. The Company currently has minimal operations and has
              incurred significant losses which have resulted in an accumulated
              deficit of $857,222 at May 31, 2003 which raises substantial doubt
              about the Company's ability to continue as a going concern. The
              accompanying financial statements do not include any adjustments
              relating to the recoverability and classification of asset
              carrying amounts or the amount and classification of liabilities
              that might result from the outcome of this uncertainty.

              It is the intent of management to seek an agreement with an
              existing operating company. Until this occurs, the Company's
              management intends to provide the Company with sufficient working
              capital to cover its operating expenses. However, there is no
              assurance that the Company will be able enter into a transaction
              with another company or that the Company's management will
              continue to provide sufficient capital to cover the operating
              expenses of the Company.

NOTE 3 -      MATERIAL EVENTS

              Related Party Transactions
              ---------------------------

              During the three months ended May 31, 2003, a related party paid
              $900 of the Company's accounts payable. The Company has imputed
              interest at 4% per annum on the balance to related parties
              outstanding longer than one year. At May 31, 2003, the Company
              owed related parties a total of $42,236, which includes interest
              of $1,852. This total amount is included in accounts payable -
              related parties.


                                       7
<PAGE>


NOTE 3 -      MATERIAL EVENTS (Continued)

              Reverse Stock Split
              -------------------

              On April 25, 2003, the Company consummated a reverse split of its
              issued and outstanding common stock on a 1-for-250 basis. As a
              result of the stock split, each two hundred fifty (250) shares of
              the Company's issued and outstanding common stock was decreased to
              one (1) fully paid and nonassessable share of common stock, $0.001
              par value per share. Fractional shares were rounded upward. The
              reverse stock split reduced the number of shares of common stock
              outstanding from 28,546,972 shares as of April 24, 2003, to
              approximately 114,214 shares. The par value of the common stock
              did not change. The shares of common stock have been retroactively
              restated in the financial statements for the reverse split for all
              periods presented.

NOTE 4 -      SUBSEQUENT EVENTS

              Name Change
              -----------

              On June 12, 2003, the Company changed its corporate name from
              Vitatonics Corp. to Rapid Bio Tests Corporation. The name change
              became effective with the filing of a Certificate of Amendment to
              the Company's Articles of Incorporation with the Nevada Secretary
              of State. The Company changed its name to reflect a change in its
              business focus.

              Increase in authorized common stock
              -----------------------------------

              On June 12, 2003, the Company filed an Amendment to its Articles
              of Incorporation, which increased its authorized number of shares
              of its $.001 par value common stock from 50,000,000 to
              120,000,000.

              The name change, reverse split and increase in authorized shares
              of common stock were approved on April 25, 2003, by unanimous
              approval of the Company's Board of Directors. In addition, on
              April 25, 2003, shareholders holding a majority of the Company's
              outstanding common stock approved those actions by written consent
              in lieu of a meeting in accordance with the relevant sections of
              the Nevada Revised Statutes.

              Change of Symbol and CUSIP Number
              ---------------------------------

              Concurrent with the above actions, the Company was issued a new
              symbol and CUSIP Number. The Company's symbol changed from "VITN"
              to "RBIO," and its CUSIP Number has changed from 928488-10-5 to
              753339-10-0.

              Resignations
              ------------

              On June 16, 2003, the following occurred: (i) Daniel McCormick
              resigned as the President and director of the Company; (ii) George
              Farquhar (effective May 23, 2003) resigned as the Secretary, Chief
              Financial Officer and director of the Company; and (iii) Dennis
              McCormick resigned as director of the Company. None of the
              resignations were the result of any disagreement with the Company
              on any matter relating to the Company's operations, policies or
              practices.



                                       8
<PAGE>


NOTE 4 -      SUBSEQUENT EVENTS (Continued)

              Appointment of New Officers and Directors
              -----------------------------------------

              On June 16, 2003, the following occurred: (i) Geoffrey V.F.
              Seaman, Ph.D. was appointed as President, Chief Executive Officer
              and a director of the Company; (ii) Paul Hemmes, Ph.D. was
              appointed as Secretary, Treasurer, Chief Financial Officer and a
              director of the Company; and (iii) David H. Regan, M.D. was
              appointed as Vice President of Medical Affairs and a director of
              the Company.

              Employment/Asset Purchase Agreements
              ------------------------------------

              On June 16, 2003, Drs. Seaman, Hemmes and Regan executed
              Employment and Asset Purchase Agreements (the "Agreements"). The
              purpose of the Agreements was to retain their management and
              technical services, including their intellectual property
              necessary to develop the Company's proposed medical testing
              products. Pursuant to the Agreements, the Company issued
              21,000,000 shares of its common stock to Dr. Seaman, 6,000,000
              shares of its common stock to Dr. Hemmes, and 3,000,000 shares of
              its common stock to Dr. Regan in exchange for their management
              services and certain intellectual property necessary to develop
              the Company's proposed products and processes. The value of the
              shares issued in exchange for these services and certain
              intellectual property will be valued based on the predecessor
              cost.

              With the assistance of its new management and the intellectual
              property transferred under the Agreements, the Company intends to
              develop, manufacture and market a series of diagnostic tests that
              can be used to detect a variety of human diseases and conditions,
              and which have utility in a variety of veterinary and agricultural
              products. The Company believes that rapid, sensitive, accurate and
              reliable diagnostic tests are necessary to respond to epidemics,
              bio-terrorism attacks and simply to cut the current high cost of
              diagnostics for general health care.



                                       9
<PAGE>

ITEM 2.  PLAN OF OPERATION
--------------------------

THIS FOLLOWING INFORMATION SPECIFIES CERTAIN FORWARD-LOOKING STATEMENTS OF
MANAGEMENT OF THE COMPANY. FORWARD-LOOKING STATEMENTS ARE STATEMENTS THAT
ESTIMATE THE HAPPENING OF FUTURE EVENTS AND ARE NOT BASED ON HISTORICAL FACT.
FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY THE USE OF FORWARD-LOOKING
TERMINOLOGY, SUCH AS "MAY", "SHALL", "WILL", "COULD", "EXPECT", "ESTIMATE",
"ANTICIPATE", "PREDICT", "PROBABLE", "POSSIBLE", "SHOULD", "CONTINUE", OR
SIMILAR TERMS, VARIATIONS OF THOSE TERMS OR THE NEGATIVE OF THOSE TERMS. THE
FORWARD-LOOKING STATEMENTS SPECIFIED IN THE FOLLOWING INFORMATION HAVE BEEN
COMPILED BY OUR MANAGEMENT ON THE BASIS OF ASSUMPTIONS MADE BY MANAGEMENT AND
CONSIDERED BY MANAGEMENT TO BE REASONABLE. OUR FUTURE OPERATING RESULTS,
HOWEVER, ARE IMPOSSIBLE TO PREDICT AND NO REPRESENTATION, GUARANTY, OR WARRANTY
IS TO BE INFERRED FROM THOSE FORWARD-LOOKING STATEMENTS.

THE ASSUMPTIONS USED FOR PURPOSES OF THE FORWARD-LOOKING STATEMENTS SPECIFIED IN
THE FOLLOWING INFORMATION REPRESENT ESTIMATES OF FUTURE EVENTS AND ARE SUBJECT
TO UNCERTAINTY AS TO POSSIBLE CHANGES IN ECONOMIC, LEGISLATIVE, INDUSTRY, AND
OTHER CIRCUMSTANCES. AS A RESULT, THE IDENTIFICATION AND INTERPRETATION OF DATA
AND OTHER INFORMATION AND THEIR USE IN DEVELOPING AND SELECTING ASSUMPTIONS FROM
AND AMONG REASONABLE ALTERNATIVES REQUIRE THE EXERCISE OF JUDGMENT. TO THE
EXTENT THAT THE ASSUMED EVENTS DO NOT OCCUR, THE OUTCOME MAY VARY SUBSTANTIALLY
FROM ANTICIPATED OR PROJECTED RESULTS, AND, ACCORDINGLY, NO OPINION IS EXPRESSED
ON THE ACHIEVABILITY OF THOSE FORWARD-LOOKING STATEMENTS. WE CANNOT GUARANTY
THAT ANY OF THE ASSUMPTIONS RELATING TO THE FORWARD-LOOKING STATEMENTS SPECIFIED
IN THE FOLLOWING INFORMATION ARE ACCURATE, AND WE ASSUME NO OBLIGATION TO UPDATE
ANY SUCH FORWARD-LOOKING STATEMENTS.

CRITICAL ACCOUNTING POLICY AND ESTIMATES. Our Management's Discussion and
Analysis of Financial Condition and Results of Operations section discusses our
financial statements, which have been prepared in accordance with accounting
principles generally accepted in the United States of America. The preparation
of these financial statements requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities at the
date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. On an on-going basis, management evaluates
its estimates and judgments, including those related to revenue recognition,
accrued expenses, financing operations, and contingencies and litigation.
Management bases its estimates and judgments on historical experience and on
various other factors that are believed to be reasonable under the
circumstances, the results of which form the basis for making judgments about
the carrying value of assets and liabilities that are not readily apparent from
other sources. Actual results may differ from these estimates under different
assumptions or conditions. The most significant accounting estimates inherent in
the preparation of our financial statements include estimates as to the
appropriate carrying value of certain assets and liabilities which are not
readily apparent from other sources. These accounting policies are described at
relevant sections in this discussion and analysis and in the notes to the
financial statements included in our Quarterly Report on Form 10-QSB for the
period ended May 31, 2003.

OUR BUSINESS. On June 16, 2003, we entered into Employment and Asset Purchase
Agreements with Dr. Geoffrey Seaman, Dr. Paul Hemmes, and Dr. David Regan to
retain their management and technical services and to purchase the intellectual
property necessary to develop our proposed medical testing products. Pursuant to
these agreements, we issued thirty million shares of our common stock to Dr.
Seaman, to Dr. Hemmes, and to Dr. Regan in exchange for their management
services and certain intellectual property necessary to develop our proposed
products and processes.

With the assistance of our new management, we intend to develop, manufacture and
market a series of rapid, sensitive, accurate and reliable diagnostic tests that
can be used to detect a variety of human diseases and conditions, and which have
utility in a variety of veterinary and agricultural products. We believe that
diagnostic tests are necessary to respond to epidemics, bio-terrorism attacks
and simply to cut the current high cost of diagnostics for general health care.


                                       10
<PAGE>

Our current management has examined a wide range of current technologies used
for rapid identification of microorganisms and toxic agents, but believes that
cutting edge and high tech approaches are unproven on a large scale and do not
meet the needs of today's environment. For these reasons, we will focus our
efforts on established technology. We propose to develop a panel of rapid,
accurate, robust and easy to perform tests for field assays and point-of-care
testing. We also propose to develop a product line of tests for the rapid and
definitive detection of infectious diseases including bacterial and viral
pathogens, as well as toxins, which our management believes can be met by rapid
latex agglutination slide tests for the primary on-site identification. We
believe that such tests are simple, easy to manufacture, inexpensive and do not
require instrumentation or electricity, nor are highly trained personnel
necessary to read the test results.

We intend to develop and bring to the market place a series of diagnostic tests
for various diseases and conditions using a latex-based technology that is novel
and proprietary. We plan to make use of technology that is protected by existing
patent applications and our management believes that the key steps in the
process are virtually impossible to reverse engineer. Our current management has
agreed to take the necessary steps to ensure that all intellectual property
necessary to conduct such tests, including patents, is transferred to us. Our
management believes that such rapid latex-based diagnostic tests represent an
effective, simple, inexpensive and versatile analysis method, which is robust,
technically mature and usable in the field. Our management believes that broad
applications for this type of testing technology include identification of
infectious diseases originating from epidemics, acts of terrorism or individual
cases at point- of- care facilities. Our management anticipates that the latex
technology platform is also broadly applicable in the medical, veterinary,
agricultural and water diagnostic test markets. Our management believes that
rapid latex tests have major advantages over many other diagnostic test
approaches in speed and costs. In the estimation of our management, such test
technology will translate to less expensive delivery of health care, not only to
the American public and other developed nations, but also in developing nations.
Because rapid latex diagnostic tests do not require laboratory facilities or
electrical power, our management believes these types of tests are ideally
suited for field-testing or use by first responders or various emergency
personnel.

We believe that an appropriate combination of the technology inventions,
identification of ideal target markets, coupled with the basic capabilities of
the principals will enable us to achieve our objectives and rapidly reduce the
latex technology platforms to practice, allowing us to proceed to
commercialization and sale of our products.

FOR THE THREE MONTH PERIOD ENDED MAY 31, 2003.
---------------------------------------------

LIQUIDITY AND CAPITAL RESOURCES. We had no cash or other current assets at May
31, 2003, and no total assets at May 31, 2003. Our total current liabilities
were $61,571 at May 31, 2003, which was represented by accounts payable of
$14,335, accounts payable to related parties of $42,236 and $5,000 in accrued
expenses. At May 31, 2003, our liabilities exceeded our assets by $61,571.

RESULTS OF OPERATIONS.

REVENUES. From inception of the development stage on March 31, 2001, through May
31, 2003, we have not realized any revenues. We hope to generate revenues in the
next twelve months by actively pursuing our newly adopted business plan and by
the eventual sale of our planned line of diagnostic testing products. However,
we cannot guarantee that our products will be ready for sale or that we will
earn any revenues within the next twelve months.

OPERATING EXPENSES. For the three months ended May 31, 2003, our total operating
expenses were $2,824 compared to total expenses of $3,255 for the corresponding
period in 2002. The expenses for the three months ended May 31, 2003 and the
corresponding period ending in 2002 were represented solely by general and
administrative expenses.

For the three months ending May 31, 2003, we also had an interest expense of
$498. Therefore our net loss was $3,322 for the three months ended May 31, 2003.
This is in comparison to $450 in interest expenses for the three months ending
May 31, 2002. For the corresponding period ending in 2002, our net loss was
$3,705. Our net loss from operations from inception of the development stage on
March 31, 2001, through May 31, 2003 was $44,662. However, our cumulative net
income from inception of the development stage on March 31, 2001, through May
31, 2003 was $131,835 which was due to a gain of $189,233 we recognized on
extinguishments of debt less interest expense of $12,736 and total expenses over
that period of $44,662.


                                       11
<PAGE>

OUR PLAN OF OPERATION FOR THE NEXT TWELVE MONTHS. As of May 31, 2003, we had no
cash resources. We have not yet generated any revenues from operations. We plan
on raising additional operating funds through the sale of our common stock. If
we are not able to raise additional funds, we may arrange for loans or other
borrowings. Our forecast of the period of time through which our financial
resources will be adequate to support our operations is a forward-looking
statement that involves risks and uncertainties, and actual results could vary
as a result of a number of factors. There is no guarantee that we will be able
to sell shares of our common stock or that we will be able to arrange for
borrowings on acceptable terms if at all.

Our plan of operation is materially dependent on our ability to continue the
development of our proposed line of diagnostic tests and raise additional
capital to market our products. We believe that we will need approximately
$400,000 to continue to develop and then market our line of diagnostic testing
products. Within the next twelve months, we hope to begin the manufacturing and
marketing of our products. We must also enter into arrangements with
manufacturers to manufacture our planned product line. Finally, we must raise
additional working capital either through the sale of our common stock or
through loans. There is no guarantee that we will be able to raise additional
capital through the sale of our common stock. Moreover, there is no guarantee
that we will be able to arrange for loans on favorable terms, or at all.

Our inability to access the capital markets or obtain acceptable financing could
harm our results of operations and financial condition. To the extent that
additional capital is raised through the sale of equity or equity-related
securities, the issuance of such securities could result in dilution of our
stockholders. We cannot guaranty that additional funding will be available on
favorable terms. If adequate funds are not available within the next 12 months,
we may be required to limit our proposed diagnostic testing development
activities or to obtain funds through entering into arrangements with
collaborative partners. If adequate funds are not available, we believe that our
officers and directors will contribute funds to pay for our expenses. Our belief
that our officers and directors will pay our expenses is based on the fact that
our officers and directors collectively own 30,000,000 shares of our common
stock, which equals approximately 99.6% of our total issued and outstanding
common stock. We believe that our officers and directors will continue to pay
our expenses as long as they maintain their ownership of our common stock. If
our officers and directors loan us operating capital, we will either execute
promissory notes to repay the funds or issue stock to those officers and
directors. We have not formulated specific repayment terms. We will negotiate
the specific repayment terms and whether repayment will be in the form of stock
when, and if, funds are advanced by any of our officers and directors.

Over the next 12 months, we plan to continue with our ongoing research and
development activities to develop our proposed line of diagnostic tests.
Specifically, we are currently studying the development of rapid diagnostic
tests for Hepatitis B, West Nile Virus and a test to establish successful
vaccinations for small pox.

a) Hepatitis B test: Our scientific team is developing an active antibody to
Hepatitis B surface antigen and plans to have rapid test kits available for
Hepatitis B surface antigen and surface antibody and Hepatitis B core antibody.

b) West Nile Virus (WN virus): We are developing and validating a rapid
microsphere-based test for WN virus, which we believe will have cost and speed
advantages over other types of immunoassay tests, and which we believe can be
deployed in the field and in rural areas since they require no instrumentation
or electricity.

c) Rapid test for effectiveness of small pox vaccination: We propose to develop
a rapid latex-based vaccinia antibody detection test for small pox vaccinations,
which we believe there will be a need for if a nationwide small pox vaccination
program is initiated.

Over the next twelve months, we do not anticipate that we will purchase or sell
any significant equipment, but rather, utilize the facilities and equipment our
scientific team currently has access to. In the event that we are able to begin
manufacturing operations, then we may need to hire additional employees or
independent contractors.


                                       12
<PAGE>

ITEM 3. CONTROLS AND PROCEDURES
-------------------------------

(a) Evaluation of disclosure controls and procedures. We maintain controls and
procedures designed to ensure that information required to be disclosed in the
reports that we file or submit under the Securities Exchange Act of 1934 is
recorded, processed, summarized and reported within the time periods specified
in the rules and forms of the Securities and Exchange Commission. Based upon
their evaluation of those controls and procedures performed within 90 days of
the filing date of this report, our chief executive officer and the principal
financial officer concluded that our disclosure controls and procedures were
adequate.

(b) Changes in internal controls. There were no significant changes in our
internal controls or in other factors that could significantly affect these
controls subsequent to the date of the evaluation of those controls by the chief
executive officer and principal financial officer.

                          PART II -- OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.
-------------------------

None.

ITEM 2. CHANGES IN SECURITIES.
------------------------------

None.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES
----------------------------------------

None.

ITEM 4.  SUBMISSION OF MATTERS TO VOTE OF SECURITY HOLDERS
----------------------------------------------------------

None.

ITEM 5.  OTHER INFORMATION
--------------------------

The following events occurred subsequent to the reporting period ending May 31,
2003 covered by this report on Form 10-QSB:

Name Change. On June 12, 2003, we changed our corporate name from Vitatonics
Corp. to Rapid Bio Tests Corporation. The name change became effective with the
filing of a Certificate of Amendment to our Articles of Incorporation with the
Nevada Secretary of State. We changed our name to reflect a change in our
business operations.

Reverse Stock Split. On April 25, 2003, our Board of Directors approved a
reverse split of its issued and outstanding common stock on a 1-for-250 basis.
As a result of the stock split, each two hundred fifty (250) shares of our
issued and outstanding common stock was decreased to one (1) fully paid and
nonassessable share of common stock, $0.001 par value per share. Fractional
shares were rounded upward. The reverse stock split reduced the number of shares
of common stock outstanding from 28,546,972 shares as of April 24, 2003, to
approximately 114,214 shares. The par value of the common stock did not change.

Increase in authorized common stock. On June 12, 2003, we filed an Amendment to
our Articles of Incorporation which increased our authorized number of shares of
our $.001 par value common stock from 50,000,000 to 120,000,000.


                                       13
<PAGE>

The name change, reverse split and increase in authorized shares of common stock
were approved on April 25, 2003, by unanimous approval of our Board of
Directors. In addition, shareholders holding a majority of our outstanding
common stock approved those actions by written consent in lieu of a meeting on
April 25, 2003, in accordance with the relevant sections of the Nevada Revised
Statutes.

Change of Symbol and CUSIP Number. Concurrent with the above actions, we were
issued a new symbol and CUSIP Number. Our symbol changed from "VITN" to "RBIO,"
and its CUSIP Number has changed from 928488-10-5 to 753339-10-0.

Resignations. On June 16, 2003, the following occurred: (i) Daniel McCormick
resigned as our President and director; (ii) George Farquhar resigned as our
Secretary and Chief Financial Officer; and (iii) Dennis McCormick resigned as
our director. None of the resignations were the result of any disagreement with
us on any matter relating to our operations, policies or practices.

Appointment of New Officers and Directors. On June 16, 2003, the following
occurred: (i) Geoffrey V.F. Seaman, Ph.D. was appointed as our President, Chief
Executive Officer; (ii) Paul Hemmes, Ph.D. was appointed as our Secretary,
Treasurer, Chief Financial Officer; and (iii) David H. Regan, M.D. was appointed
as our Vice President of Medical Affairs and a director.

Employment/Asset Purchase Agreements. On June 16, 2003, Drs. Seaman, Hemmes and
Regan executed Employment and Asset Purchase Agreements (the "Agreements"). The
purpose of the Agreements was for us to retain their management and technical
services, including their intellectual property necessary to develop our
proposed medical testing products. Pursuant to the Agreements, we issued
21,000,000 shares of our common stock to Dr. Seaman, 6,000,000 shares of our
common stock to Dr. Hemmes, and 3,000,000 shares of our common stock to Dr.
Regan in exchange for their management services and certain intellectual
property necessary to develop our proposed products and processes. With the
assistance of our new management and the intellectual property transferred under
the Agreements, we intend to develop, manufacture and market a series of
diagnostic tests which we believe can be used to detect a variety of human
diseases and conditions, and which we believe have utility in a variety of
veterinary and agricultural products.

ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K
------------------------------------------

Exhibits:
--------

Exhibit 99.1      Certification Pursuant to 18 U.S.C. Section 1350, as Adopted
                  Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
                  Executed by our Chief Executive Officer

Exhibit 99.2      Certification Pursuant to 18 U.S.C. Section 1350, as Adopted
                  Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
                  Executed by our Chief Financial Officer

Form 8-K:
--------

Our Form 8-K filed on June 18, 2003, announcing, among other events, the
acquisition of assets and appointment of new officers and directors.



                                       14
<PAGE>



                                   SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

                                        Rapid Bio Tests Corporation,
                                        a Nevada corporation



July 15, 2003                  By:      /s/  Geoffrey V.F. Seaman
                                        ----------------------------------------
                                        Geoffrey V.F. Seaman

                               Its:     Chief Executive Officer, President,
                                        Director




                                       15
<PAGE>



CERTIFICATIONS
---------------

I, Geoffrey V.F. Seaman, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Rapid Bio Tests
Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

          a) designed such disclosure controls and procedures to ensure that
          material information relating to the registrant, including its
          consolidated subsidiaries, is made known to us by others within those
          entities, particularly during the period in which this quarterly
          report is being prepared;

          b) evaluated the effectiveness of the registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

          c) presented in this quarterly report our conclusions about the
          effectiveness of the disclosure controls and procedures based on our
          evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

          a) all significant deficiencies in the design or operation of internal
          controls which could adversely affect the registrant's ability to
          record, process, summarize and report financial data and have
          identified for the registrant's auditors any material weaknesses in
          internal controls; and

          b) any fraud, whether or not material, that involves management or
          other employees who have a significant role in the registrant's
          internal controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.


Date: July 15, 2003




/s/ Geoffrey V.F. Seaman
-------------------------
Geoffrey V.F. Seaman
Chief Executive Officer




                                       16
<PAGE>



CERTIFICATIONS
--------------

I, Paul R. Hemmes, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Rapid Bio Tests
Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

          a) designed such disclosure controls and procedures to ensure that
          material information relating to the registrant, including its
          consolidated subsidiaries, is made known to us by others within those
          entities, particularly during the period in which this quarterly
          report is being prepared;

          b) evaluated the effectiveness of the registrant's disclosure controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

          c) presented in this quarterly report our conclusions about the
          effectiveness of the disclosure controls and procedures based on our
          evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

          a) all significant deficiencies in the design or operation of internal
          controls which could adversely affect the registrant's ability to
          record, process, summarize and report financial data and have
          identified for the registrant's auditors any material weaknesses in
          internal controls; and

          b) any fraud, whether or not material, that involves management or
          other employees who have a significant role in the registrant's
          internal controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.



Date: July 15, 2003



/s/ Paul R. Hemmes
----------------------
Paul R. Hemmes
Chief Financial Officer